BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34273278)

  • 1. Human papillomavirus vaccination history and diagnosis of cervical intraepithelial neoplasia grade ≥2 severe lesions among a cohort of women who underwent colposcopy in Kaiser Permanente Southern California.
    Lonky NM; Xu L; Da Silva DM; Felix JC; Chao C
    Am J Obstet Gynecol; 2021 Dec; 225(6):656.e1-656.e11. PubMed ID: 34273278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
    Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
    Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
    Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
    Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program.
    Sahlgren H; Elfström KM; Lamin H; Carlsten-Thor A; Eklund C; Dillner J; Elfgren K
    Am J Obstet Gynecol; 2020 Mar; 222(3):253.e1-253.e8. PubMed ID: 31585095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study.
    Alder S; Megyessi D; Sundström K; Östensson E; Mints M; Belkić K; Arbyn M; Andersson S
    Am J Obstet Gynecol; 2020 Feb; 222(2):172.e1-172.e12. PubMed ID: 31473226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of guidelines for observational management of cervical intraepithelial neoplasia 2 in young women.
    Dempster-Rivett K; Innes CR; Simcock BJ; Harker D; Williman JA; Van Der Griend RA; Whitehead M; Hibma M; Lawton BA; Fitzgerald P; Dudley NM; Petrich S; Faherty J; Bergzoll C; Eva L; Sadler L; Pather S; Wrede CD; Sykes PH
    Am J Obstet Gynecol; 2020 Sep; 223(3):408.e1-408.e11. PubMed ID: 32109465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.
    Elfgren K; Elfström KM; Naucler P; Arnheim-Dahlström L; Dillner J
    Am J Obstet Gynecol; 2017 Mar; 216(3):264.e1-264.e7. PubMed ID: 27825977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.
    Silver MI; Gage JC; Schiffman M; Fetterman B; Poitras NE; Lorey T; Cheung LC; Katki HA; Locke A; Kinney WK; Castle PE
    Cancer Prev Res (Phila); 2018 Mar; 11(3):165-170. PubMed ID: 29437696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
    Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
    J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Lei J; Ploner A; Lehtinen M; Sparén P; Dillner J; Elfström KM
    Br J Cancer; 2020 Jul; 123(1):155-160. PubMed ID: 32362659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years.
    Sykes PH; Simcock BJ; Innes CR; Harker D; Williman JA; Whitehead M; van der Griend RA; Lawton BA; Hibma M; Fitzgerald P; Dudley NM; Petrich S; Eva L; Bergzoll C; Kathuria J; McPherson G; Tristram A; Faherty J; Hardie D; Robertson A; Robertson V; Pather S; Wrede CD; Gastrell F; Fentiman G; John M; White E; Parker C; Sadler L
    Am J Obstet Gynecol; 2022 Feb; 226(2):222.e1-222.e13. PubMed ID: 34534506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of cervical intraepithelial neoplasia in women with atypical squamous or glandular cells of undetermined significance cytology: a prospective study.
    Wensveen C; Kagie M; Veldhuizen R; De Groot C; Denny L; Zwinderman K; Trimbos B
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):883-9. PubMed ID: 12911453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.